Drugs / GILORALIMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04807972 | May 2021 → Mar 2024 | malignant pancreatic neoplasm | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03818542 | Jan → Sep 2020 | head and neck cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03893955 | May 2019 → Mar 2027 expected | metastatic neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02988960 | Feb 2017 → Sep 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GILORALIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594517 ↗ |
| Known as | ABBV-927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02988960 ↗ |
| Known as | PR-1614645 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594517 ↗ |
| Action | Activate | “Tumor necrosis factor receptor superfamily member 5 agonist” CHEMBL4594517 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594517 ↗ |
| Route | Intravenous | “escalating intravenous (IV) doses of ABBV-927” NCT02988960 ↗ |
| Target | CD40 | “Tumor necrosis factor receptor superfamily member 5 agonist” CHEMBL4594517 ↗ |